152 related articles for article (PubMed ID: 31526356)
1. Oxidant and Antioxidant Effects of Gentisic Acid in a
Trindade V; Balter H
Curr Radiopharm; 2020; 13(2):107-119. PubMed ID: 31526356
[TBL] [Abstract][Full Text] [Related]
2. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279
[TBL] [Abstract][Full Text] [Related]
3. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
4. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
5. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
Ocak M; Helbok A; von Guggenberg E; Ozsoy Y; Kabasakal L; Kremser L; Decristoforo C
Nucl Med Biol; 2011 Feb; 38(2):171-9. PubMed ID: 21315272
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
7. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.
de Blois E; Chan HS; de Zanger R; Konijnenberg M; Breeman WA
Appl Radiat Isot; 2014 Feb; 85():28-33. PubMed ID: 24365877
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC.
de Blois E; Chan HS; Konijnenberg M; de Zanger R; Breeman WA
Curr Top Med Chem; 2012; 12(23):2677-85. PubMed ID: 23339763
[TBL] [Abstract][Full Text] [Related]
9. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
11. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
12. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
13. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
[TBL] [Abstract][Full Text] [Related]
14.
Rizvi SFA; Naqvi SAR; Roohi S; Sherazi TA; Rasheed R
Mol Biol Rep; 2018 Dec; 45(6):1759-1767. PubMed ID: 30143975
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant activity and free radical scavenging reactions of gentisic acid: in-vitro and pulse radiolysis studies.
Joshi R; Gangabhagirathi R; Venu S; Adhikari S; Mukherjee T
Free Radic Res; 2012 Jan; 46(1):11-20. PubMed ID: 22023109
[TBL] [Abstract][Full Text] [Related]
16. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
17. Selective site-specific fenton oxidation of methionine in model peptides: evidence for a metal-bound oxidant.
Dufield DR; Wilson GS; Glass RS; Schöneich C
J Pharm Sci; 2004 May; 93(5):1122-30. PubMed ID: 15067689
[TBL] [Abstract][Full Text] [Related]
18. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
[TBL] [Abstract][Full Text] [Related]
19. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
20. Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
Ghosh A; Woolum K; Kothandaraman S; Tweedle MF; Kumar K
Molecules; 2019 Aug; 24(16):. PubMed ID: 31398865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
